ClinicalTrials.gg

Program

Bispecific Antibody GEN1079

Its studies are led by Genmab.

Furthest: phase 1, since Jan 28, 20261 company-led study, 1 open or runningNext primary completion: Jan 2031 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Genmab11 open or runningphase 1since Jan 28, 2026Jan 28, 2026Jan 2031phase 1 · NCT07387068

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 28, 2026First study: phase 1 study in Advanced Solid TumorsFirst studyNCT07387068 · 121 planned · United States, Spain

Ahead

  1. Jan 2031Primary completion: phase 1 study in Advanced Solid TumorsNCT07387068

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07387068Advanced Solid Tumors · United States, Spain1RecruitingJan 2031121

How it is read

Names in the registry

  • “GEN1079”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.